This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Stocks in Motion

Updated from 2:22 p.m.

Shares of Genta (GNTA) were among the worst-performing health and pharmaceutical stocks Tuesday, falling 50% after the biopharmaceutical company said Sanofi-Aventis (SNY) ended the companies' joint development agreement.

The two companies will work together to develop Genasense, Genta's cancer drug, until May 8, 2005. After that, Genta will continue the development of the drug on its own. When the companies first entered the agreement in 2002, Aventis was seeking a late-stage development opportunity that could potentially be launched in the near term. Earlier this year, however, regulators rejected the drug with respect to melanoma. As a result, Aventis said that it could no longer support the development of Genasense. Shares of Genta traded down $1.30 to $1.30.

Fonar (FONR - Get Report) rose 9.7% after the maker of MRI equipment swung to a first-quarter profit. The company posted a profit of 1 cent a share on sales of $25.1 million. A year ago the company posted a loss of 5 cents a share on sales of $13.3 million. Strong sales of the company's Upright MRI units led to the impressive first-quarter results. Shares traded up 11 cents to $1.25.

Shares of BriteSmile (BSML) fell 16.7% after the company posted weak third-quarter results and warned of a fourth-quarter shortfall as well. During the third quarter, the teeth-whitening technology company posted a loss of 24 cents a share on sales of $11.9 million. Analysts were expecting a loss of 9 cents a share on sales of $12.7 million. Looking ahead, BriteSmile forecast that fourth-quarter sales would decline both sequentially and on a year-over-year basis. Analysts had been expecting sales of $14.7 million. BriteSmile said the sales shortfall reflects soft demand experienced during the first part of the fourth quarter. Shares traded down $1.50 to $7.50.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
FONR $9.77 1.60%
MRK $54.95 0.97%
PFE $33.25 2.50%
SLXP $172.81 0.09%
AAPL $112.80 2.80%

Markets

Chart of I:DJI
DOW 16,654.77 +369.26 2.27%
S&P 500 1,981.79 +41.28 2.13%
NASDAQ 4,798.8210 +101.2850 2.16%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs